panepoxydone has been researched along with ER-Negative PR-Negative HER2-Negative Breast Cancer in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arora, R; Dean-Colomb, W; Gary, BD; McClellan, S; Owen, LB; Piazza, GA; Reed, E; Tan, M; Xi, Y; Yates, C | 1 |
| Arora, R; Dean-Colomb, W; Karanam, B; Schmitt, D; Tan, M; Yates, C | 1 |
2 other study(ies) available for panepoxydone and ER-Negative PR-Negative HER2-Negative Breast Cancer
| Article | Year |
|---|---|
Panepoxydone targets NF-kB and FOXM1 to inhibit proliferation, induce apoptosis and reverse epithelial to mesenchymal transition in breast cancer.
Topics: Antineoplastic Agents; Apoptosis; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Movement; Cell Proliferation; Cell Survival; Epithelial-Mesenchymal Transition; Female; Forkhead Box Protein M1; Forkhead Transcription Factors; Humans; NF-kappa B; Phosphorylation; Signal Transduction; Triple Negative Breast Neoplasms; Up-Regulation | 2014 |
Inhibition of the Warburg effect with a natural compound reveals a novel measurement for determining the metastatic potential of breast cancers.
Topics: Adenosine Triphosphate; Apoptosis; Breast Neoplasms; Bridged Bicyclo Compounds, Heterocyclic; Cell Line, Tumor; Cell Proliferation; Female; Glycolysis; Humans; L-Lactate Dehydrogenase; MCF-7 Cells; Membrane Potential, Mitochondrial; Neoplasm Metastasis; Oxidative Phosphorylation; Signal Transduction; Triple Negative Breast Neoplasms | 2015 |